Effects of Short-Term Creatine Supplementation on Cognitive Function in Healthy Young Adults
Public ClinicalTrials.gov record NCT07867041. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effects of Short-Term, High-Dosage Creatine Supplementation on Cognitive Measures Following Mental Fatigue in Healthy Young Adults
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study examined whether short-term creatine supplementation affects cognitive function in healthy young adults. Participants were randomly assigned to take either creatine monohydrate or a placebo for 10 days. Participants took 30 grams per day, divided into six 5-gram doses. Before and after the supplementation period, participants completed cognitive tests designed to assess areas such as memory, attention, reaction time, and processing speed. Participants also completed a 30-minute mentally challenging Stroop task, and brain oxygenation was measured during cognitive testing using functional near-infrared spectroscopy (fNIRS). The purpose of the study was to determine whether 10 days of high-dose creatine supplementation improves cognitive performance compared with placebo following a mentally challenging task.
Study identification
- NCT ID
- NCT07867041
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 24 participants
Conditions and interventions
Conditions
Interventions
- Creatine Monohydrate Dietary Supplement
- Maltodextrin Placebo Dietary Supplement
Dietary Supplement
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 10, 2024 (Actual)
- Primary completion
- Dec 3, 2024 (Actual)
- Completion
- Dec 3, 2024 (Actual)
- Last update posted
- Oct 9, 2026
2024
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Northern Iowa | Cedar Falls | Iowa | 50614 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07867041, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 9, 2026 · Synced Oct 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07867041 live on ClinicalTrials.gov.